Literature DB >> 28000059

Interleukin-33 Expression does not Correlate with Survival of Gastric Cancer Patients.

Wenwei Hu1,2,3, Xiaodong Li1,2,3, Qing Li4, Yan Tan4, Bin Xu2,3, Quanqin Xie2, Xu Deng2, Binfeng Lu5, Jingting Jiang6,7, Changping Wu8.   

Abstract

The aim of the study was to investigate IL-33 expression in gastric cancer (GC) and its association with the clinical characteristics and the prognosis. IL-33 protein in tumor and corresponding adjacent tissues were detected by immunohistochemistry in 179 GC patients and clinical features plus prognostic value were analyzed via Pearson's chi-square test and Kaplan-Meier test in Cox proportional hazards model, respectively. IL-33 protein levels were significantly lower in tumor tissues than adjacent tissues (29.05% vs. 78.77%, χ 2  = 89.05, P < 0.001). The positive rate of IL-33 in the ulcerative type group was the lowest among all groups (P < 0.05). IL-33 levels were correlated with age (P = 0.025) and invasion depth (P = 0.030) while not significantly associated with the overall survival of GC patients. IL-33 expression is associated with age and invasive depth of GC patients but not an independent risk factor of prognosis.

Entities:  

Keywords:  Clinical characteristics; Gastric cancer; Interleukin-33; Survival

Mesh:

Substances:

Year:  2016        PMID: 28000059     DOI: 10.1007/s12253-016-0167-1

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  17 in total

1.  Serum- and oncoprotein-mediated induction of a gene with sequence similarity to the gene encoding carcinoembryonic antigen.

Authors:  R Klemenz; S Hoffmann; A K Werenskiold
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

2.  Clinicopathologic characteristics of gastric carcinoma in elderly patients: a comparison with young patients.

Authors:  Dong-Yi Kim; Jae-Kyoon Joo; Seong-Yeob Ryu; Young-Kyu Park; Young-Jin Kim; Shin-Kon Kim
Journal:  World J Gastroenterol       Date:  2005-01-07       Impact factor: 5.742

3.  IL-33-induced JNK pathway activation confers gastric cancer chemotherapy resistance.

Authors:  Xiao-Lei Ye; Ya-Rong Zhao; Guo-Bin Weng; Yi-Chen Chen; Xue-Ni Wei; Jing-Ping Shao; Hui Ji
Journal:  Oncol Rep       Date:  2015-04-03       Impact factor: 3.906

4.  Serum interleukin-33 levels in patients with gastric cancer.

Authors:  Pinghu Sun; Qiwen Ben; Shuiping Tu; Wenjie Dong; Xiaoguang Qi; Yunlin Wu
Journal:  Dig Dis Sci       Date:  2011-06-04       Impact factor: 3.199

5.  Annual report on status of cancer in China, 2011.

Authors:  Wanqing Chen; Rongshou Zheng; Hongmei Zeng; Siwei Zhang; Jie He
Journal:  Chin J Cancer Res       Date:  2015-02       Impact factor: 5.087

6.  IL-33 Promotes Gastric Cancer Cell Invasion and Migration Via ST2-ERK1/2 Pathway.

Authors:  Xi-Xiang Yu; Zhe Hu; Xian Shen; Li-Yang Dong; Wei-Zhong Zhou; Wen-Hao Hu
Journal:  Dig Dis Sci       Date:  2015-02-06       Impact factor: 3.199

7.  High Serum Levels of the Interleukin-33 Receptor Soluble ST2 as a Negative Prognostic Factor in Hepatocellular Carcinoma.

Authors:  Dominik Bergis; Valentin Kassis; Annika Ranglack; Verena Koeberle; Albrecht Piiper; Bernd Kronenberger; Stefan Zeuzem; Oliver Waidmann; Heinfried H Radeke
Journal:  Transl Oncol       Date:  2013-06-01       Impact factor: 4.243

8.  IL-33 mediates antigen-induced cutaneous and articular hypernociception in mice.

Authors:  Waldiceu A Verri; Ana T G Guerrero; Sandra Y Fukada; Daniel A Valerio; Thiago M Cunha; Damo Xu; Sérgio H Ferreira; Foo Y Liew; Fernando Q Cunha
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-04       Impact factor: 11.205

9.  Polarization of ILC2s in peripheral blood might contribute to immunosuppressive microenvironment in patients with gastric cancer.

Authors:  Qingli Bie; Pan Zhang; Zhaoliang Su; Dong Zheng; Xinyu Ying; Yumin Wu; Huijian Yang; Deyu Chen; Shengjun Wang; Huaxi Xu
Journal:  J Immunol Res       Date:  2014-03-04       Impact factor: 4.818

10.  Tristetraprolin inhibits gastric cancer progression through suppression of IL-33.

Authors:  Kaiyuan Deng; Hao Wang; Ting Shan; Yigang Chen; Hong Zhou; Qin Zhao; Jiazeng Xia
Journal:  Sci Rep       Date:  2016-04-14       Impact factor: 4.379

View more
  6 in total

1.  IL-33 promotes gastric tumour growth in concert with activation and recruitment of inflammatory myeloid cells.

Authors:  Chau P Tran; Michelle Scurr; Louise O'Connor; Jon N Buzzelli; Garrett Z Ng; Sharleen Chung Nien Chin; Lincon A Stamp; Toshinari Minamoto; Andrew S Giraud; Louise M Judd; Philip Sutton; Trevelyan R Menheniott
Journal:  Oncotarget       Date:  2022-06-01

2.  IL‑33/ST2 promotes the malignant progression of gastric cancer via the MAPK pathway.

Authors:  Ning Huang; Xing Cui; Wen Li; Chunlai Zhang; Liqing Liu; Jinxing Li
Journal:  Mol Med Rep       Date:  2021-03-24       Impact factor: 2.952

3.  Clinical implications of interleukins-31, 32, and 33 in gastric cancer.

Authors:  Qing-Hua Liu; Ji-Wei Zhang; Lei Xia; Steven G Wise; Brett David Hambly; Kun Tao; Shi-San Bao
Journal:  World J Gastrointest Oncol       Date:  2022-09-15

Review 4.  The Pleiotropic Immunomodulatory Functions of IL-33 and Its Implications in Tumor Immunity.

Authors:  Claudia Afferni; Carla Buccione; Sara Andreone; Maria Rosaria Galdiero; Gilda Varricchi; Gianni Marone; Fabrizio Mattei; Giovanna Schiavoni
Journal:  Front Immunol       Date:  2018-11-13       Impact factor: 7.561

5.  Proinflammatory Interleukin-33 Induces Dichotomic Effects on Cell Proliferation in Normal Gastric Epithelium and Gastric Cancer.

Authors:  Laura Francesca Pisani; Gian Eugenio Tontini; Carmine Gentile; Beatrice Marinoni; Isabella Teani; Nicoletta Nandi; Pasquale Creo; Emanuele Asti; Luigi Bonavina; Maurizio Vecchi; Luca Pastorelli
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

6.  Interleukin 33 Triggers Early Eosinophil-Dependent Events Leading to Metaplasia in a Chronic Model of Gastritis-Prone Mice.

Authors:  Carlo De Salvo; Luca Pastorelli; Christine P Petersen; Ludovica F Buttò; Kristine-Ann Buela; Sara Omenetti; Silviu A Locovei; Shuvra Ray; Hannah R Friedman; Jacob Duijser; Wei Xin; Abdullah Osme; Fabio Cominelli; Ganapati H Mahabeleshwar; Jason C Mills; James R Goldenring; Theresa T Pizarro
Journal:  Gastroenterology       Date:  2020-10-01       Impact factor: 22.682

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.